FDA label
What is Glatopa used for?
Glatopa contains glatiramer acetate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Glatopa?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Glatopa, injection, solution
Indications and Usage, quoted from the label by Sandoz Inc (ANDA090218). Cross-references to other label sections are left out.
Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Source: DailyMed label, set id 5f01e40a-b6f6-40fb-b37c-3d06f1428e86, version 30, effective July 15, 2026. NDC 0781-3234, one of 4 listings for this product.
Questions
What is Glatopa used for?
The FDA label says: “Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Glatopa
- Is Glatopa a controlled substance?Federal schedule
- What is Glatiramer Acetate used for?FDA label uses
- Is Glatiramer Acetate a controlled substance?Federal schedule
- Generic for CopaxoneFDA Orange Book
- Glatopa Medicare Part D coverageBy plan and state
- NDC 0781-3234Glatopa NDC record
- NDC 0781-3250Glatopa NDC record
- NDC 63629-8815Glatopa NDC record